Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and CMML
NCT03289910Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2018
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of veliparib in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) and myeloproliferative disorder (MPD) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Number of Participants With a Response (CR/CRi) up to 7 months. Started Sep 2018; status: active, not recruiting.
02
Drugs
veliparib
03
Conditions
acute myeloid leukemia (AML)chronic myelomonocytic leukemia (CMML)myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on NCT03289910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03289910.